MeSH term
Frequency | Condition_Probility | Animals | 21 | 0.0 |
Humans | 74 | 0.0 |
COS Cells | 3 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 32 | 0.0 |
English Abstract | 16 | 0.0 |
Female | 29 | 0.0 |
Hypertension, Pulmonary/diagnosis | 2 | 100.0 |
Male | 32 | 0.0 |
Time Factors | 13 | 0.0 |
Base Sequence | 13 | 0.0 |
Cattle | 3 | 0.0 |
Codon/genetics | 2 | 0.0 |
Conserved Sequence | 4 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Laterality/physiology | 3 | 5.0 |
Reaction Time/physiology | 3 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Adult | 28 | 0.0 |
Comparative Study | 16 | 0.0 |
*Magnetoencephalography | 3 | 37.0 |
*Reading | 2 | 20.0 |
Transfection | 4 | 0.0 |
Chronic Disease | 3 | 0.0 |
Middle Aged | 27 | 0.0 |
Respiration | 4 | 7.0 |
Respiratory Function Tests | 7 | 4.0 |
Risk Factors | 7 | 0.0 |
Aged | 14 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
*Palliative Care | 2 | 25.0 |
Survival Rate | 2 | 0.0 |
Child | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Pregnancy | 3 | 0.0 |
3T3 Cells | 4 | 0.0 |
Mice | 10 | 0.0 |
Models, Genetic | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Repressor Proteins/genetics/*physiology | 2 | 5.0 |
Signal Transduction | 3 | 0.0 |
Amino Acid Sequence | 11 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Phenotype | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
*Transcription Factors | 6 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Promoter Regions (Genetics)/*physiology | 2 | 2.0 |
Adolescent | 8 | 0.0 |
Blood Pressure Monitoring, Ambulatory | 2 | 4.0 |
Echocardiography | 2 | 0.0 |
Syndrome | 2 | 0.0 |
Pulmonary Circulation/*physiology | 2 | 15.0 |
Recurrence | 2 | 0.0 |
*Respiration | 3 | 8.0 |
Cell Cycle | 2 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Hela Cells | 4 | 0.0 |
Immunoblotting | 2 | 0.0 |
*Repressor Proteins | 5 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Genotype | 2 | 0.0 |
Bronchoscopy | 2 | 3.0 |
Esophageal Neoplasms/complications | 3 | 75.0 |
Lung Neoplasms/complications | 2 | 25.0 |
Radiography, Interventional | 2 | 50.0 |
*Stents/adverse effects | 2 | 40.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Treatment Outcome | 6 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
DNA Primers | 3 | 0.0 |
Acoustic Stimulation | 3 | 3.0 |
DNA Primers/genetics | 3 | 0.0 |
Gene Expression | 2 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Calcium/blood | 3 | 1.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
*Trans-Activators | 2 | 0.0 |
DNA | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Electroencephalography | 2 | 0.0 |
Magnetoencephalography | 2 | 28.0 |
Calcium/metabolism | 2 | 0.0 |
Eukaryotic Cells | 2 | 4.0 |
Rabbits | 3 | 0.0 |
Escherichia coli | 2 | 0.0 |
Expressed Sequence Tags | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Lung Volume Measurements | 2 | 9.0 |
Hemodynamic Processes | 2 | 1.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Photometry | 2 | 12.0 |
Sodium/*blood | 2 | 9.0 |
Blood Pressure | 2 | 0.0 |